A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report

被引：6
|
作者：
Wang, Jianzheng [1 ]
Li, Qingli [2 ]
Lv, Huifang [1 ]
Nie, Caiyun [1 ]
Chen, Beibei [1 ]
Xu, Weifeng [1 ]
Yang, Tiejun [3 ]
Zhang, Yinping [4 ]
Tu, Shuiping [2 ]
Chen, Xiaobing [1 ]
机构：
[1] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China
[3] Zhengzhou Univ, Henan Canc Hosp, Dept Urol Surg, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Zhengzhou Univ, Henan Canc Hosp, Dept Pathol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词：
PD-1; complete response; advanced; urothelial carcinoma; case report; CELL LUNG-CANCER; ADVERSE EVENTS; PNEUMONITIS; CHEMOTHERAPY; GEMCITABINE; CISPLATIN; TOXICITY; EFFICACY;
D O I：
10.3389/fonc.2021.671416
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The prognosis of patients with advanced urothelial carcinoma is dismal. Platinum-based chemotherapy is still the main first-line treatment for advanced urothelial carcinoma, while immunotherapy can be used as a first-line treatment option for people who cannot tolerate platinum. Immunotherapy is preferred in the second-line treatment of bladder urothelial carcinoma. PD-1 inhibitors (Pembrolizumab, nivolumab and atezolizumab) and PD-L1 inhibitors (Ddurvalumab and avelumab) have not been approved for the treatment of advanced urothelial cancer in China. We describe a patient with advanced urothelial carcinoma experienced disease progression after gemcitabine chemotherapy. Following a treatment of domestic PD-1 inhibitor (sintilimab), the patient achieved a durable complete response with mild toxicity. This case indicates that PD-1 inhibitor sintilimab might be a second-line treatment choice for advanced urothelial carcinoma.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study
    Miller, Natalie J.
    Khaki, Ali Raza
    Diamantopoulos, Leonidas N.
    Bilen, Mehmet A.
    Santos, Victor
    Agarwal, Neeraj
    Morales-Barrera, Rafael
    Devitt, Michael
    Nelson, Ariel
    Hoimes, Christopher J.
    Shreck, Evan
    Assi, Hussein
    Gartrell, Benjamin A.
    Sankin, Alex
    Rodriguez-Vida, Alejo
    Lythgoe, Mark
    Pinato, David J.
    Drakaki, Alexandra
    Joshi, Monika
    Velho, Pedro Isaacsson
    Hahn, Noah
    Liu, Sandy
    Buznego, Lucia Alonso
    Duran, Ignacio
    Moses, Marcus
    Jain, Jayanshu
    Murgic, Jure
    Barata, Pedro
    Tripathi, Abhishek
    Zakharia, Yousef
    Galsky, Matthew D.
    Sonpavde, Guru
    Yu, Evan Y.
    Lyman, Gary H.
    Grivas, Petros
    JOURNAL OF UROLOGY, 2020, 204 (01): : 63 - 69
  • [32] Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with HER2 gene amplification: A case report
    Jiang, Qi
    Xie, Mi-Xue
    Zhang, Xiao-Chen
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (03) : 594 - 599
  • [33] Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1/L1 inhibitor therapy
    Hepp, Zsolt
    Shah, Sonali N.
    Liang, Shang-Ying
    Tan, Katherine
    Balakrishna, Shreya
    FUTURE ONCOLOGY, 2021, 17 (32) : 4343 - 4353
  • [34] PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report
    Lim, Olivia
    Maher, Eamonn
    Miller, Daniel D.
    DRUGS IN R&D, 2024, 24 (02) : 353 - 357
  • [35] Acquired Perforating Dermatosis Induced by PD-1 Inhibitor: A Case Report
    Liu, Xiaoyan
    Wang, Huayang
    Wan, Yinsheng
    Guo, Ying
    Shan, Shi-Jun
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2021, 43 (12) : 942 - 944
  • [36] PD-1 Blockade in Advanced Adrenocortical Carcinoma
    Raj, Nitya
    Zheng, Youyun
    Kelly, Virginia
    Katz, Seth S.
    Chou, Joanne
    Do, Richard K. G.
    Capanu, Marinela
    Zamarin, Dmitriy
    Saltz, Leonard B.
    Ariyan, Charlotte E.
    Untch, Brian R.
    O'Reilly, Eileen M.
    Gopalan, Anuradha
    Berger, Michael F.
    Olino, Kelly
    Segal, Neil H.
    Reidy-Lagunes, Diane L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (01) : 71 - +
  • [37] PD-1 Blockade in Advanced Adrenocortical Carcinoma
    Raj, Nitya
    Zheng, Youyun
    Kelly, Virginia
    Katz, Seth
    Chou, Joanne
    Do, Richard
    Capanu, Marinela
    Zamarin, Dmitriy
    Saltz, Leonard
    Ariyan, Charlotte
    Untch, Brian
    O'Reilly, Eileen
    Gopalan, Anuradha
    Berger, Michael
    Olino, Elly
    Segal, Neil
    Reidy, Diane
    PANCREAS, 2020, 49 (03) : 484 - 484
  • [38] PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
    Sonpavde, Guru
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1073 - 1074
  • [39] Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient
    Zhang, Er-lei
    Zhang, Zun-yi
    Li, Jian
    Huang, Zhi-yong
    ONCOTARGETS AND THERAPY, 2020, 13 : 12477 - 12487
  • [40] Advanced ampullary carcinoma showing complete response to S-1: Report of a case
    Nobutsugu Abe
    Masanori Sugiyama
    Hideaki Mizuno
    Yutaka Suzuki
    Tadahiko Masaki
    Toshiyuki Mori
    Yutaka Atomi
    Surgery Today, 2010, 40 : 574 - 577
12345